Marvel Biosciences Corp. MRVL.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.15% | 5.90% | -8.99% | -24.49% | 20.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.83% | -50.20% | 11.78% | 47.11% | 4.51% |
| Operating Income | -40.83% | 50.20% | -11.78% | -47.11% | -4.51% |
| Income Before Tax | 275.87% | 37.61% | -21.00% | -100.49% | 20.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 275.87% | 37.61% | -21.00% | -100.49% | 20.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 275.87% | 37.61% | -21.00% | -100.49% | 20.04% |
| EBIT | -40.83% | 50.20% | -11.78% | -47.11% | -4.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 230.00% | 51.32% | 4.35% | -53.27% | 29.82% |
| Normalized Basic EPS | 124.00% | 52.08% | 0.00% | -52.24% | 30.56% |
| EPS Diluted | 230.00% | 51.32% | 4.35% | -53.27% | 29.82% |
| Normalized Diluted EPS | 124.00% | 52.08% | 0.00% | -52.24% | 30.56% |
| Average Basic Shares Outstanding | 37.44% | 29.47% | 24.08% | 30.79% | 12.58% |
| Average Diluted Shares Outstanding | 37.44% | 29.47% | 24.08% | 30.79% | 12.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |